Mayne Pharma sold US Retail Generics Portfolio to DR. Reddys for US$90 million

Mayne Pharma Group Limited (ASX: MYX) has announced that it has sold its US Retail Generics Portfolio to Dr. Reddy's Laboratories SA, a DR. Reddy's Laboratories Ltd. subsidiary. Approximately US$93.8 million of cash is received, including the upfront cash consideration of US$24 million for working capital and accrued liabilities of US$21 million related to selling the products in the US market before closing.

Transaction costs are currently expected at approximately US$1 million, plus between US$6 million and a one-time restructuring cost of US$11 million. The contingent milestone was also agreed upon for up to US$15 million.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com